Margaret E Helmuth1, Qian Liu2, Marc N Turenne2, Jeong M Park3, Murewa Oguntimein4, Sarah K Dutcher4, Rajesh Balkrishnan5, Pratima Sharma6, Jarcy Zee2, Alan B Leichtman2, Abigail R Smith2. 1. Arbor Research Collaborative for Health, Ann Arbor, Michigan; margaret.helmuth@arborresearch.org. 2. Arbor Research Collaborative for Health, Ann Arbor, Michigan. 3. College of Pharmacy, University of Michigan, Ann Arbor, Michigan. 4. Center for Drug Evaluation and Research, US Food and Drug Administration, Washington, DC; and. 5. Public Health Sciences, School of Medicine, University of Virginia, Charlottesville, Virginia. 6. Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
Abstract
BACKGROUND AND OBJECTIVES: Immunosuppressive medications are critical for maintenance of graft function in transplant recipients but can represent a substantial financial burden to patients and their insurance carriers. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: To determine whether availability of generic immunosuppressive medications starting in 2009 may have alleviated some of that burden, we used Medicare Part D prescription drug events between 2008 and 2013 to estimate the average annualized per-patient payments made by patients and Medicare in a large national sample of kidney, liver, and heart transplant recipients. Repeated measures linear regression was used to determine changes in payments over the study period. RESULTS: Medicare Part D payments for two commonly used immunosuppressive medications, tacrolimus and mycophenolic acid (including mycophenolate mofetil and mycophenolate sodium), decreased overall by 48%-67% across organs and drugs from 2008 to 2013, reflecting decreasing payments for brand and generic tacrolimus (21%-54%), and generic mycophenolate (72%-74%). Low-income subsidy payments, which are additional payments made under Medicare Part D, also decreased during the study period. Out-of-pocket payments by patients who did not receive the low-income subsidy decreased by more than those who did receive the low-income subsidy (63%-79% versus 24%-44%). CONCLUSIONS: The decline in payments by Medicare Part D and by transplant recipients for tacrolimus and mycophenolate between 2008 and 2013 suggests that the introduction of generic immunosuppressants during this period has resulted in substantial cost savings to Medicare and to patients, largely reflecting the transition from brand to generic products.
BACKGROUND AND OBJECTIVES: Immunosuppressive medications are critical for maintenance of graft function in transplant recipients but can represent a substantial financial burden to patients and their insurance carriers. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: To determine whether availability of generic immunosuppressive medications starting in 2009 may have alleviated some of that burden, we used Medicare Part D prescription drug events between 2008 and 2013 to estimate the average annualized per-patient payments made by patients and Medicare in a large national sample of kidney, liver, and heart transplant recipients. Repeated measures linear regression was used to determine changes in payments over the study period. RESULTS: Medicare Part D payments for two commonly used immunosuppressive medications, tacrolimus and mycophenolic acid (including mycophenolate mofetil and mycophenolate sodium), decreased overall by 48%-67% across organs and drugs from 2008 to 2013, reflecting decreasing payments for brand and generic tacrolimus (21%-54%), and generic mycophenolate (72%-74%). Low-income subsidy payments, which are additional payments made under Medicare Part D, also decreased during the study period. Out-of-pocket payments by patients who did not receive the low-income subsidy decreased by more than those who did receive the low-income subsidy (63%-79% versus 24%-44%). CONCLUSIONS: The decline in payments by Medicare Part D and by transplant recipients for tacrolimus and mycophenolate between 2008 and 2013 suggests that the introduction of generic immunosuppressants during this period has resulted in substantial cost savings to Medicare and to patients, largely reflecting the transition from brand to generic products.
Authors: Roger W Evans; William H Applegate; David M Briscoe; David J Cohen; Christopher C Rorick; Barbara T Murphy; Joren C Madsen Journal: Clin J Am Soc Nephrol Date: 2010-09-16 Impact factor: 8.237
Authors: Lisa M McDevitt-Potter; Basma Sadaka; Eric M Tichy; Christin C Rogers; Steven Gabardi Journal: Transplantation Date: 2011-09-27 Impact factor: 4.939
Authors: Eugene F Yen; Karen Hardinger; Daniel C Brennan; Robert S Woodward; Niraj M Desai; Jeffrey S Crippin; Brian F Gage; Mark A Schnitzler Journal: Am J Transplant Date: 2004-10 Impact factor: 8.086
Authors: Matthew Kadatz; John S Gill; Jagbir Gill; Richard N Formica; Scott Klarenbach Journal: J Am Soc Nephrol Date: 2019-11-08 Impact factor: 10.121